Sales $2m , Staff costs $4m for the quarter! How can you justify this?
No major revenues forecast until 2025 and reliant on FDA approvals.
CEO needs to step up and make some tough decisions on this company moving forward.
Pathetic, and no accountability!
- Forums
- ASX - By Stock
- GSS
- Ann: Quarterly Activities/Appendix 4C Cash Flow Report
GSS
genetic signatures limited
Add to My Watchlist
2.67%
!
36.5¢

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-3
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
36.5¢ |
Change
-0.010(2.67%) |
Mkt cap ! $82.90M |
Open | High | Low | Value | Volume |
36.5¢ | 36.5¢ | 36.5¢ | $160 | 438 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 19601 | 36.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
37.5¢ | 32411 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 14601 | 0.365 |
2 | 9513 | 0.360 |
3 | 30509 | 0.350 |
1 | 1683 | 0.300 |
1 | 25000 | 0.270 |
Price($) | Vol. | No. |
---|---|---|
0.375 | 32411 | 1 |
0.380 | 3086 | 1 |
0.390 | 20000 | 1 |
0.395 | 5000 | 1 |
0.400 | 111918 | 2 |
Last trade - 13.38pm 04/07/2025 (20 minute delay) ? |
Featured News
GSS (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online